文献速递白血病

60岁以上急性髓系白血病患者强化化疗后合并症、突变谱与结局的关系:不同风险评分的评估

Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores.
PubMed 文献 · Am J Hematol · 2023-04-05

研究纳入91例接受强化诱导治疗的60岁及以上急性髓系白血病(AML)患者,用二代测序在77个基因中检出323个突变。多状态模型显示FLT3、IDH2、RUNX1、TET2突变与完全缓解可能性较高相关,STAG2突变与原发难治相关,DNMT3A、FLT3、IDH2、TP53突变与复发后死亡相关;Ferrara不适合标准与体能状态是短期结局的最佳预测指标,基因组分类对长期结局预测更好。

要点

  • 91例≥60岁AML患者中,二代测序在77个基因检出323个突变,中位每例4个突变。
  • Ferrara不适合标准与体能状态对2个月生存的曲线下面积均为82,是短期结局最佳预测指标。
  • Patel风险分层在5年随访中对无事件生存和总生存的C指数均为0.63,长期预测表现最佳。

核心结论

  • 多数主要用于年轻患者的基因组预后分类对老年患者仍有分类价值,但因突变谱不同而适用程度较低。
  • 应专门为60岁以上患者设计纳入体能状态、合并症和细胞遗传学/分子数据的特异性预后分类。

研究设计与样本

  • 研究纳入91例60岁及以上接受强化诱导治疗的急性髓系白血病患者,采用二代测序在77个基因中检出323个突变。

主要发现

  • 每例患者中位突变数为4个,NPM1、FLT3、TET2和DNMT3A为最常突变基因。
  • 多状态模型显示FLT3、IDH2、RUNX1和TET2突变与获得完全缓解的可能性较高相关。
  • STAG2突变与原发难治性疾病相关,DNMT3A、FLT3、IDH2和TP53突变与复发后死亡相关。
  • Ferrara不适合标准与体能状态对2个月生存的曲线下面积均为82,是短期结局的最佳预测指标。
  • 基因组分类对长期结局预测更好,Patel风险分层在5年随访中对无事件生存和总生存的C指数均为0.63。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to evaluate how comorbidities and molecular landscape relate to outcome in patients with acute myeloid leukemia (AML) aged 60 years or older who received intensive induction therapy. In 91 patients, 323 mutations were identified in 77 genes by next-generation sequencing, with a median of four mutations per patient, with NPM1, FLT3, TET2, and DNMT3A being the most frequently mutated genes. A multistate model identified FLT3, IDH2, RUNX1, and TET2 mutations as associated with a higher likelihood of achieving complete remission while STAG2 mutations were associated with primary refractory disease, and DNMT3A, FLT3, IDH2, and TP53 mutations with mortality after relapse. Ferrara unfitness criteria and performance status were the best predictors of short-term outcome (area under the curve = 82 for 2-month survival for both parameters), whereas genomic classifications better predicted long-term outcome, with the Patel risk stratification performing the best over the 5-year follow-up period (C-index = 0.63 for event-free and overall survival). We show that most genomic prognostic classifications, mainly used in younger patients, are useful for classifying older patients, but to a lesser extent, because of different mutational profiles. Specific prognostic classifications, incorporating performance status, comorbidities, and cytogenetic/molecular data, should be specifically designed for patients over 60 years.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Bachelot A, Bouvier A, Riou J, et al. Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores. Am J Hematol. 2023. PMID: 36964937. doi:10.1002/ajh.26917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。